Početna › Neuroblastom › Massachusetts
Kliničke studije za Neuroblastom u državi Massachusetts
13 studija za Neuroblastom traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 3
Do 30 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
U tijeku regrutacija
Sve dobne skupine · Oba spola · Ažurirano 1. lis 2026. · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
U tijeku regrutacijaFaza 1
9 Months – 30 Years · Oba spola · Ažurirano 3. ruj 2026. · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 3
365 Days – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 2 do 21 godina · Oba spola · Ažurirano 11. kol 2026. · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 1 do 30 godina · Oba spola · Ažurirano 22. srp 2026. · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
U tijeku regrutacijaFaza 2
Od 1 do 31 godina · Oba spola · Ažurirano 20. srp 2026. · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 14. srp 2026. · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
U tijeku regrutacijaOpažajna studija
31 Days – 99 Years · Oba spola · Ažurirano 23. ožu 2026. · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Do 17 godina · Oba spola · Ažurirano 10. velj 2026. · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
12 Months – 29 Years · Oba spola · Ažurirano 26. pro 2025. · NCT06803875Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.